Please login to the form below

Not currently logged in
Email:
Password:

UK/Russian pharma firm launches

Global pharmaceutical company, Pro Bono Bio, has launched today with funding from UK-based Celtic Pharma and the state-owned Russian Corporation of Nanotechnologies (RusNano)

Global pharmaceutical company, Pro Bono Bio, has launched today with funding from UK-based Celtic Pharma and the state-owned Russian Corporation of Nanotechnologies (RusNano).

The company said it intends to support a 'unique humanitarian mission' with products to be priced in different areas based on the region's ability to pay.

Free drug donations will be available to countries in Africa based on the success of products sold Western Europe.

The launch of Pro Bono Bio comes at the same time as UK Prime Minister David Cameron's visit to Russia.

He said: "This is a great example of UK/Russia collaboration at the cutting edge of R&D. It demonstrates how British businesses can work together with their Russian counterparts to expand into new areas, creating jobs and prosperity here in the UK."

As part of the company's development, Pro Bono Bio said it intends to build a manufacturing plant in the UK. A further facility is also planned for Moscow.

The company is to launch its first product Flexiseq, a nanotechnology based treatment for osteoarthritis, in the UK today, with further plans to release drugs for skin disorders in the coming months.

Other pipeline products for the company include blood factors for the treatment of haemophilia as well as antibiotics for the treatment of infections such as Clostridium difficile, MRSA and tuberculosis.

12th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics